Imunon has reported new immunogenicity and safety data from its proof-of-concept Phase I trial’s ongoing analyses of the IMNN ...
Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.
The meeting cancellation came one day before the CDC issued its weekly MMWR report, a scientific update on the latest ...
Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...
Most people will recover from viruses like the flu, COVID, and RSV without medical care, but some patients might need a trip ...
The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.
Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...
A recent modification to the contract would have allowed Vaxart to invoice BARDA for the remaining $230 million or so for ...